Abstract
BackgroundA randomised field trial was conducted on an Austrian farrow-to-finish farm for one year to compare the efficacy of two commercial Mycoplasma hyopneumoniae vaccines. 585 piglets either received the one-shot formulation in group 1 (Hyogen®, 23.9 days of age) or a two-shot vaccine (Stellamune® Mycoplasma, 4.3 and 24.0 days of age) in group 2. Assessment of vaccine efficacy was evaluated by regression analyses through cough monitoring from nursery to slaughter, average daily weight gain from inclusion to slaughter, antibiotic treatment rate (ATR), mortality rate, and lung lesion scoring at slaughter.ResultsIn general, coughing was more frequent during late nursery and finishing. No significant differences were found in the coughing index (0.02 vs 0.03) and mean average daily weight gain (560 vs 550 g) between the two groups. ATR was higher in group 2 (3.8 vs 9.6%). At the slaughterhouse check, significant differences in the prevalence of bronchopneumonia (62.9 vs 71.2%) could be found. Extension of lung lesions was also significantly lower in group 1 in terms of enzootic pneumonia (EP) values (p = 0.000, z = − 4.269). There were no significant differences in the rate of scarred lungs (20.0 vs 24.0%) or those affected by dorsocaudal pleurisy (36.8 vs 34.3%).ConclusionsThis trial demonstrated that Hyogen® was superior to Stellamune® Mycoplasma in reducing (I) the prevalence of bronchopneumonic lungs and those affected by cranioventral pleurisy, (II) the extension and severity of EP-like lung lesions, and (III) the rate of antibiotically treated animals against respiratory disease.
Highlights
A randomised field trial was conducted on an Austrian farrow-to-finish farm for one year to compare the efficacy of two commercial Mycoplasma hyopneumoniae vaccines. 585 piglets either received the one-shot formulation in group 1 (Hyogen®, 23.9 days of age) or a two-shot vaccine (Stellamune® Mycoplasma, 4.3 and 24.0 days of age) in group 2
The first stage of pathogenesis is the adhesion of M. hyopneumoniae to the ciliated epithelial cells of the respiratory mucosa by means of the adhesins P97, P102, and P159 [1,2,3]
Animals and trial setting The study was performed on a closed combined family-owned single-site farm in Lower Austria, housing 84 Large White sows working in a 3-weeks rhythm. 600 fattening places were assigned to 10 pens in one stable and one air space
Summary
A randomised field trial was conducted on an Austrian farrow-to-finish farm for one year to compare the efficacy of two commercial Mycoplasma hyopneumoniae vaccines. 585 piglets either received the one-shot formulation in group 1 (Hyogen®, 23.9 days of age) or a two-shot vaccine (Stellamune® Mycoplasma, 4.3 and 24.0 days of age) in group 2. A randomised field trial was conducted on an Austrian farrow-to-finish farm for one year to compare the efficacy of two commercial Mycoplasma hyopneumoniae vaccines. Mycoplasma hyopneumoniae (M. hyopneumoniae) is considered a primary pathogen of the porcine respiratory system, playing an important role in the porcine respiratory disease complex. M. hyopneumoniae is able to produce hydrogen peroxide, leading to inflammatory lesions at the Possible methods to prevent and control M. hyopneumoniae are optimization of management practices such. Cvjetković et al Porcine Health Management (2018) 4:19 as all-in/all-out production and multisite-operations, the use of antimicrobials, and vaccination. Tetracyclines and macrolides are used most frequently to control and treat respiratory disease induced by M. hyopneumoniae [8]. Antibiotics are neither able to eliminate M. hyopneumoniae from the respiratory tract nor restore already developed lung lesions [5]. The massive and often not justified use of antibiotics has led to a rise in antibiotic resistances, which has important drawbacks for animal and human health
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
